Covidien, a leading global provider of healthcare products, confirmed the immediate availability of its new and improved Magellan(TM) Safety Hypodermic Needle. The modified design, which is now shipping to all customers, is in stock and available at all Covidien distribution centers in the United States. Beginning today, the previous needle model is no longer being produced or sold.
Covidien, a leading global provider of healthcare products, confirmed the immediate availability of its new and improved Magellan(TM) Safety Hypodermic Needle. The modified design, which is now shipping to all customers, is in stock and available at all Covidien distribution centers in the United States. Beginning today, the previous needle model is no longer being produced or sold.
Jeff Hunt, President, Patient Care and Safety Products, Covidien said, The feedback on the updated Magellan Safety Hypodermic Needle has been extremely positive. We have increased capacity to allow for a smooth transition with our existing customers, and this expansion has enabled us to meet the growing demands of the safety needle market.
The conversion to the improved Magellan Safety Hypodermic Needle has been ongoing since October, and Covidien has worked closely with its existing customers and distribution partners to ensure a smooth transition and uninterrupted supply.
